AMLX logo
AMLX NASDAQ US

Amylyx Pharmaceuticals, Inc. - Common Stock

Healthcare · Pharmaceuticals Website · IPO Jan 2022
$14.95
▲ +$0.60 (+4.18%)
Vol 1.3M
7
Quality Score
fail
Mkt Cap
$1.3B
ROE
-69.0%
Margin
-94.6%
D/E
0.00
Beta
-0.34
52W
$3–$17

Wall Street Consensus

18 analysts · Apr 2026
8
Strong Buy
8
Buy
2
Hold
0
Sell
0
Strong Sell
88.9%
Buy Rating

Price Chart

Similar Stocks

INVA
Innoviva Inc
P/E 11.7
$1.5B
ANIP
ANI Pharmaceuticals Inc
P/E 43.7
$1.8B
RAPP
Rapport Therapeutics Inc
$1.4B
HRMY
Harmony Biosciences Holdings Inc
P/E 11.6
$2.2B
MBX
MBX Biosciences Inc
$1.4B
TRVI
Trevi Therapeutics Inc
$1.6B

About Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals - біофармацевтична компанія, що спеціалізується на розробці ліків від нейродегенеративних захворювань, таких як бічний аміотрофічний склероз (БАС). Їхній флагманський продукт, Relyvrio, отримав схвалення для лікування БАС, що робить їх ключовим гравцем на ринку ліків від цього захворювання. Конкурентною перевагою є їхня зосередженість на невирішених медичних потребах у сфері нейродегенеративних захворювань та інноваційний підхід до розробки ліків.

Earnings

Beat rate: 75.0%
Next Report May 06, 2026
EPS Estimate: $-0.34
Quarter EPS Est EPS Act Surprise
Mar 2026 $-0.34 — —
Dec 2025 $-0.37 $-0.30 +$0.07
Sep 2025 $-0.46 $-0.37 +$0.09
Jun 2025 $-0.45 $-0.46 $-0.01

Quarterly Revenue & Earnings

Quarter 2024-0… 2024-1… 2025-0… 2025-0… 2025-0… 2025-1…
Revenue — -$665K — — — —
Net Income — -$37.5M -$35.9M -$41.4M -$34.4M -$33.0M

Fundamentals Trend

Metric 2025-06-30 2025-09-02 2025-10-02 2025-11-03 2025-12-03 2026-01-02
ROE (TTM) -102.8% -102.8% -102.8% -102.8% -69.0% -69.0%
P/E (TTM) — — — — — —
Net Margin — -94.6% -94.6% -94.6% -94.6% -94.6%
Gross Margin — 82.8% 82.8% 82.8% 82.8% 82.8%
D/E Ratio 0.00 0.00 0.00 0.00 0.00 0.00
Current Ratio 8.72 8.72 8.72 8.72 13.70 13.70

Key Ratios

ROA (TTM)
-61.5%
P/S (TTM)
6.75
P/B
1.6
EPS (TTM)
$-1.80
CF/Share
$0.04
Rev Growth 3Y
+574.3%
52W High
$16.96
52W Low
$2.60
$2.60 52-Week Range $16.96

Financial Health

Free Cash Flow
-$28.0M
Net Debt
-$220.7M
Cash
$226.7M
Total Debt
$6.0M
As of Dec 31, 2025

How does AMLX compare to Pharmaceuticals peers?

Peer group: Micro-cap Pharmaceuticals (All) · 171 companies

AMLX AARD ACB ACRS ADIL

AMLX valuation vs Pharmaceuticals peers

P/E ratio
—
▼ 0% below peers (22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
6.8
▲ 36% above peers (5.0)
vs Peers
vs Industry
Pricier
P/B ratio
1.6
▼ 26% below peers (2.1)
vs Peers
vs Industry
Pricier
Div yield
—
▼ 0% below peers (2.0%)
vs Peers
vs Industry
Low yield

AMLX profitability vs Pharmaceuticals peers

ROE
-69.0%
▼ 27% below peers (-54.3%)
vs Peers
vs Industry
Below avg
Net margin
-94.6%
▼ 100% below peers (-47.4%)
vs Peers
vs Industry
Weak
Gross margin
82.8%
▲ 21% above peers (68.3%)
vs Peers
vs Industry
Weak
ROA
-61.5%
▼ 64% below peers (-37.4%)
vs Peers
vs Industry
Weak

AMLX financial health vs Pharmaceuticals peers

D/E ratio
0.0
▼ 100% below peers (1.5)
vs Peers
vs Industry
Low debt
Current ratio
13.7
▲ 308% above peers (3.4)
vs Peers
vs Industry
Strong liquidity
Beta
-0.3
▼ 137% below peers (0.9)
vs Peers
vs Industry
More volatile

AMLX fundamentals radar

AMLX Peer median Industry

AMLX profitability vs leverage

Bubble size = market cap · X = net margin · Y = D/E ratio

AMLX vs peers: key metrics

Insider Activity

Neutral
Buys
0
Sells
0
BEDROSIAN CAMILLE L
Officer · Mar 05
95990 shs
FRATES JAMES MATTHEW
Chief Financial Officer · Mar 05
95990 shs
COHEN JOSHUA BARRY
Chief Executive Officer · Mar 05
248865 shs
KLEE JUSTIN B
Chief Executive Officer · Mar 05
248865 shs
MAZZARIELLO GINA
Officer · Mar 05
74660 shs
BEDROSIAN CAMILLE L
Officer · Mar 02
6461 shs
FRATES JAMES MATTHEW
Chief Financial Officer · Mar 02
7909 shs
COHEN JOSHUA BARRY
Chief Executive Officer · Mar 02
29282 shs
KLEE JUSTIN B
Chief Executive Officer · Mar 02
29282 shs
MAZZARIELLO GINA
Officer · Mar 02
6844 shs
Last 90 days

Top Holders

Top 5: 41.53%
FMR, LLC
14.94%
$223.8M
Blackrock Inc.
8.19%
$122.7M
Perceptive Advisors Llc
7.50%
$112.3M
TCG Crossover Management, L…
5.65%
$84.6M
Vanguard Group Inc
5.25%
$78.7M
As of Dec 31, 2025

Latest News

No related news yet